Sagimet Biosciences(SGMT) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Sagimet Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates Phase 1 clinical trial to evaluate the PK of a combination of denifanstat and resmetirom ongoing with data readout expected 1H 2026 First-in-human Phase 1 clinical trial of FASN inhibitor TVB-3567 ongoing Ascletis announced completion of its pre-NDA consultation with China's NMPA and plans to submit an NDA for denifanstat in China for treatment of moderate-to-severe acne vulgaris San Mateo, Calif., N ...